Loosers can not intimidate NASA in Kamba Land ......voters .

Wiper Democratic Movement Chairman resigned  and immediately cited it was due to the mishandling of Kitui county #WiperPrimaries that saw him trounced by Governor Julius Malombe by a very big margin . 



Senator David Musila  resigned as the Wiper Democratic Party Chairman, a day after Governor Julius Malombe was announced winner of the party’s Kitui nomination. Many people from the county said the Senator was beaten full and square and now what he was doing was to intimidate the party leadership to try arm twist the results which was unacceptable according to sources .

" Leave a lone him, if Hon Kalonzo left NASA he could have gone alone and now this Musila and people like Nyenze can not hold us at ransom when our principal is working hard to put us on Kenyan map politically, we are in NASA to stay . Ask them if those Luhyas, Kisii, Coastal communities , Kelenjins , etc are equally not Kenyas ? " .  The angry youths chanted saying he had done for them nothing and now his time was up. They said his defeat had nothing to do with any political malpractice but because the people were tired with him and the Governor had done a good job.

NASA SHALL WIN THE AUGUST POLLS.

NASA's lineup is the best for the country as it brings hope for a united Kenya. Jubilee government mainly drawn from two communities of Kikuyu and Nandi of Rift Valley regions respectively, tended to awoken ethnicity that has caused tensions and suspicions which many people say opposition will wipe away and the best for the country's integration .

WHO Malaria vaccine to be piloted in Africa as Kenya, Ghana and Malawi take part.

Ghana, Kenya, and Malawi to take part in WHO malaria vaccine pilot programme

The World Health Organization Regional Office for Africa (WHO/AFRO) announced on April 24, 2017, that Ghana, Kenya, and Malawi will partner with WHO in the Malaria Vaccine Implementation Programme (MVIP) that will make the RTS,S vaccine available in selected areas of the three countries, beginning in 2018. WHO/AFRO announced the countries at a high-level forum in Nairobi, Kenya, organized by WHO and the Ministry of Health of Kenya in advance of World Malaria Day.

The MVIP is being coordinated and led by WHO in close collaboration with Ministries of Health in the participating countries and a range of in-country and international partners. The MVIP will take place in Ghana, Kenya, and Malawi, beginning in 2018, with preparations already underway.

By 2020, the MVIP is expected to provide initial insights on the programmatic feasibility of delivering the RTS,S/AS01 vaccine candidate (trade name Mosquirix™) in real-life settings and on the safety profile of RTS,S in the context of routine use. The MVIP will continue monitoring feasibility and safety through its expected conclusion in 2022, while also generating results on the vaccine’s impact on childhood survival. The results of the MVIP will help inform future decisions on the wider-scale deployment of the vaccine.

RTS,S is expected to be approved by the National Regulatory Authorities (NRAs) in each of the three countries participating in MVIP for use in the context of the pilot evaluation and Phase 4 studies.

Visit the WHO/AFRO website (link is external) to read their press release.

Development of RTS.S

RTS,S is the candidate malaria vaccine furthest along in development globally, the outcome of a long-standing collaboration between PATH and GSK that began in 2001. RTS,S is the first and, to date, the only vaccine to show a protective effect against malaria among young children in Phase 3 clinical trials.

RTS,S is an injectable vaccine that provides partial protection against malaria in young children. Like vaccines generally, RTS,S aims to trigger the body’s own immune system to defend against disease, in this case, malaria caused by Plasmodium falciparum, the most deadly species of the malaria parasite globally and the most prevalent in Africa. The large-scale Phase 3 efficacy and safety trial of RTS,S (which concluded in January 2014) showed that the vaccine candidate could provide meaningful public health benefit by reducing the burden of malaria when used alongside currently available interventions such as bednets and insecticides.

Beginning in the 1980s, early development was undertaken by GSK, working in close collaboration with the Walter Reed Army Institute of Research. In January 2001, GSK and PATH’s Malaria Vaccine Initiative (MVI), with grant money from the Bill & Melinda Gates Foundation to PATH, entered into a public-private partnership to develop the vaccine for infants and young children in sub-Saharan Africa.

Between mid-2009 and early 2014, MVI, GSK, and leading research centers in Africa conducted a Phase 3 efficacy and safety trial of RTS,S that involved 15,459 infants and young children at 11 sites in seven countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania). Today, partners continue to work on next steps for RTS,S along the pathway to possible implementation.

World Health Organization recommendation for pilot implementation of RTS,S

In October 2015, WHO jointly convened the Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Committee (MPAC) to review all evidence regarding RTS,S relevant for global policy. SAGE/MPAC jointly recommended large-scale pilot implementation of RTS,S occur among children aged 5 to 17 months in 3–5 settings of moderate-to-high transmission in sub-Saharan Africa. WHO officially adopted the SAGE/MPAC recommendations in January 2016.

Visit the WHO website to read their position paper (link is external).

Scientific opinion by European regulators

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for RTS,S in July 2015. The CHMP gives scientific opinions, in cooperation with the WHO, on medicinal products for human use that are intended exclusively for markets outside of the European Union.

Final results from the Phase 3 efficacy trial of RTS,S, published in The Lancet, showed that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. 

Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up.

I Swear If ISIS Bomb any City in RUSSIA, Every ISLAMISTS Will Die in half an hour – President Putin vows

Russian President Putin Said “to Forgive The Terrorists Is Up To God, But To Send Them To See God Is My Duty!”

SAGGING GENERATION

 This generation need to pull up their pants its that simple counsel !

What has changed in their brains or advancement leads to walking necked ? 

Its time to face this generation directly , tell them they are badly mannered, poorly dressed , unprofessional and lacking basic decorum before it finally becomes berserk. 

The whole thing is not  notions about  employable people who wear certain clothes, have certain manners, and generally look and act a certain way but about helping people conform to acceptable  standards, to a degree regardless of one's occupation .

This is not decency !